IP Library Granted Patent US 8,722,724
Granted Patent B2
US 8,722,724 · App. 12/183,007 · Granted May 13, 2014

Compositions and methods for treating neoplastic diseases

Inventors: Kenneth C. Anderson (Wellesley, MA); Dharminder Chauhan (Natick, MA); Michael A. Palladino (Olivenhain, CA)
Assignees: Triphase Research and Development I Corp.; Dana-Farber Cancer Institute, Inc.
A61K31/407
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,724
App. No.
12/183,007
Granted
May 13, 2014
Kind
B2
Abstract

Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.

Claims (12)

1. A method of treating a neoplastic disease, comprising:

administering to a patient inflicted with the neoplastic disease a compound of formula (I) or a pharmaceutically acceptable salt thereof:

wherein X is selected from the group consisting of fluorine, chlorine, bromine or iodine, and

wherein the neoplastic disease is resistant to a proteasome inhibitor.

2. The method of claim 1 , wherein X is chlorine.

3. The method of claim 1 , wherein the compound of formula (I) has the structure of formula (II):

4. The method of claim 1 , wherein the neoplastic disease is cancer.

5. The method of claim 4 , wherein the cancer is selected from the group consisting of breast cancer, sarcoma, leukemia, ovarian cancer, uretal cancer, bladder cancer, prostate cancer, colon cancer, rectal cancer, stomach cancer, lung cancer, lymphoma, multiple myeloma, pancreatic cancer, liver cancer, kidney cancer, endocrine cancer, skin cancer, melanoma, angioma, and brain or central nervous system (CNS) cancer.

6. The method of claim 5 , wherein the cancer is selected from the group consisting of multiple myeloma, colorectal carcinoma, prostate carcinoma, breast adenocarcinoma, non-small cell lung carcinoma, and an ovarian carcinoma or melanoma.

7. The method of claim 6 , wherein the cancer is a multiple myeloma.

8. The method of claim 1 , wherein the patient is a human.

9. The method of claim 1 , wherein the proteasome inhibitor is bortezomib.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2020
From: CELGENE TRI A HOLDINGS LTD.
To: CELGENE INTERNATIONAL II SARL
Reel/Frame 051741/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2018
From: 1096271 B.C. UNLIMITED LIABILITY COMPANY
To: CELGENE TRI A HOLDINGS LTD.
Reel/Frame 046047/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2018
From: CELGENE RESEARCH AND DEVELOPMENT I ULC, FORMERLY KNOWN AS TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
To: 1096271 B.C. UNLIMITED LIABILITY COMPANY
Reel/Frame 046047/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2017
From: NEREUS PHARMACEUTICALS, INC.
To: TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
Reel/Frame 041698/0404 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2013
From: ANDERSON, KENNETH C.; CHAUHAN, DHARMINDER
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 031384/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2013
From: NEREUS PHARMACEUTICALS, INC.
To: TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
Reel/Frame 030670/0412 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2012
From: PALLADINO, MICHAEL A.
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 028618/0850 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2012
From: PALLADINO, MICHAEL A.
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 028618/0860 →
Continuity (3)
Continuation 11293354 · Dec 2, 2005
Provisional Application 60633161 · Dec 3, 2004
Related Publication 20090036390A1 · Feb 5, 2009